IMV Inc IMVIF

RE:RE:RE:RE: Webcast

[Breakthorough]

What I got from the answers to JB (WF) and JP (HCW) is mainly: - They want to analyze the translational data before making a decision for Registrational Trial. It should be done in 2021 (in nov 12 they said Type B meeting with FDA after actual trial is complete in Q1). - Asked ab the possibility of more PR coming from actual SD, Ors acknowledged that it was possible. BUT that the important thing was the duration of benefit. It compared it with first FDA approval of Pembro (Melanoma). - Ors also suggested that the path of DPX could be the same of Pembro in relation to future passing to prior lines of therapy.